ACEi, angiotensin antagonists, diuretics Flashcards
RAAS pathway
where is renin produced
in the juxtaglomerular cells in kidney
what causes renin release
drop in BP in pre-glomerular arteries (systolic <90 mmHg)
low NaCl in kidney’s distal tubule
increased SNS activity (beta1)
where is angiotensinogen produced
liver
where is angiotensin converting enzyme (ACE) produced
kidney
what does angiotensin II cause
aldosterone secretion
vasoconstriction
what does angiotensin II mediated vasoconstriction cause
increased peripheral vascular resistance
–> increased BP
what does angiotensin II mediated aldosterone secretion cause
increased retention of Na and water –> increased BP
where does renin cleave angiotensinogen
between Leu-Val aa
where does ACE cleave angiotensin I
between Phe-His aa
where does aminopeptidase cleave angiotensin II
between Asp-Arg
what is the name of renin inhibitor drug
Aliskiren
aliskiren moa
direct inhibitor renin
decreases formation of angiotensin I from angiotensinogen
aliskiren clinical use
not 1st line tx for htn
aliskiren effect
drops BP bc it inhibits renin
aliskiren problems
do not use in pregnant and nursing mothers
what is common identifying factor of ACEi
all ACEi ends in -pril
what are the sulfahydryl-containing ACEi structurally related to Captopril
fentiapril, pivalopril, zofenopril, alacepril
what are the dicarboxyl-containing ACEi structurally related to Enalapril
lisinopril, benazepril, quinapril, moexipril, ramipril, trandolapril, perindopril, spirapril, pentopril, cilazapril
what are the phosphorous-containing ACEi
Fosinopril
ACEi action
inhibits angiotensin converting enzyme
ACEi effects
reduces vasoconstriction caused by angiotensin II
reduce Na and Cl retention caused by aldosterone
reduce total peripheral resistance
reduces myocardial mitogenic activity
ACEi clinical use
1st line tx for htn, hf
ACEi and ARBs in different races
particular useful in whites but not african americans as monotherapy for htn but appropriate for hf
ACEi in pts with diff. diseases
better for pts with diabetes than thiazides
better for pts with ischemic heart disease than direct vasodilators
ACEis AEs
cough, angioedema, hyperkalemia
why should ACEi not be used in pregnancy
can cause fetal hypotension, renal failure, mortality
what may reduce ACEi effectiveness
NSAIDs
what can ACEi/ARBs also be used in
renal artery stenosis, but not if GFR drops by more than 30%
bradykinin effects
causes vasodilation, in part mediated by PGI2
why can ACEi cause hyperkalemia
decreased production of aldosterone
why can ACEi cause angioedema of lips and tongue
accumulation of bradykinin
which race has bigger risk of angioedema from ACEi
black pts have a 4-5x higher risk than white pts
what is common identifying factor of ARBs
all ARBs end in -sartan
ARBs affinity
blocks angiotensin II receptors with higher affinity for AT1 than AT2 receptor
ARBs potency ranking
candesartan = omesartan > irbesartan = eprosartan > telmisartan = valsartan > EXP 3174 (active metabolite of losartan) > losartan
lisinopril info
t1/2 = 12h
not a prodrug
enalapril info
prodrug, hydrolyzed to active diacid enalaprilat
captopril info
thiol-containing
not a prodrug
t1/2 <3h
what design is ARBs based off
carboxy terminus of angiotensin II
ARBs structure activity relationship
acidic group: o-phenylcarboxylic acid (or the tetrazole isostere) or carboxylic acid
substituted imidazole or isosteric equivalent
in some cases, a second carboxylic acid group
ARBs effects
decreased myocardial and vascular remodeling
decreased cardiomyocyte apoptosis
reduce total peripheral resistance
ARBs clinical use
1st line monotherapy for htn IN pts who cannot tolerate ACEi
ARBs AEs
hypotension, hyperkalemia, lower rate of angioedema, fetal pathologies, reduction in GFR
why do ARBs not cause persistent cough
ARBs do not inhibit breakdown of bradykinin
ARBs are particularly useful in pts with:
diabetes
ischemic heart disease
pts with CKD
what are the aldosterone (mineralocorticoid) receptor antagonists (aka potassium sparing diuretics)
spironolactone, eplerenone
K sparing diuretic moa
blocks reabsorption of sodium
what causes K sparing diuretic’s effectiveness in hf
not primarily due to diuretic effect.
increases production of aldosterone which promotes development of cardiac hypertrophy, remodeling, fibrosis.
maintenance of normal K levels –> reduces risk of arrhythmias.
K sparing diuretic clinical use
chronic hf.
aldosteronism.
not monotherapy for htn but used to reduce hypokalemia.
K sparing diuretic AEs
hyperkalemia.
spironolactone can cause gynecomastia and impotence due to interaction with other steroid receptors.
what is the thiazide diuretic drug
chlorthalidone
thiazides moa
diuretic blocking sodium-chloride symporter (NCC) on distal convoluted tubule
what does thiazide lower when used long term
peripheral vascular resistance –> lower BP
thiazide clinical use
1st line monotherapy for mild-moderate htn
what race is thiazides useful in
african americans
what pts do you not use thiazides for
pts with diabetes, hyperlipidemia, gout
thiazide AEs
hypokalemia, metabolic alkalosis, hyperuricemia, hypercalcemia, hyperglycemia, hyperlipidemia
what does thiazides do initially
reduce blood volume and cardiac output
–> decrease BP
which diuretic is not recommended as 1st line monotherapy for htn
loop diuretics
why are K sparing diuretics not recommended as 1st line monotherapy for htn
weak acting.
associated with hyperkalemia
what htn meds can you use for pregnancy
methyldopa
beta blockers (e.g. labetalol, metoprolol)